Jeroen Janssen

DR., (Principal Investigator)

20042019
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2004 2019

A Semi-Mechanistic Population Pharmacokinetic/Pharmacodynamic Model of Bortezomib in Pediatric Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Dorlo, T. P. C., Janssen, J., Niewerth, D., Wilhelm, A. J., Zwaan, C. M., Beijnen, J. H., Attarbaschi, A., Baruchel, A., Fagioli, F., Klingebiel, T., de Moerloose, B., Palumbo, G., von Stackelberg, A., Kaspers, G. J. L. & Huitema, A. D. R., 2019, In : Clinical Pharmacokinetics.

Research output: Contribution to journalArticleAcademicpeer-review

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

Kreutzman, A., Yadav, B., Brummendorf, T. H., Gjertsen, B. T., Lee Hee, M., Janssen, J., Kasanen, T., Koskenvesa, P., Lofti, K., Markevärn, B., Olsson-Strömberg, U., Stentoft, J., Stenke, L., Söderlund, S., Udby, L., Richter, J., Hjorth-Hansen, H. & Mustjoki, S., 2019, In : OncoImmunology.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Neutrophil hypersegmentation ironed out

Meijer, R. I., Stoffels, J. M. J., Janssen, J. J. W. M. & Kooter, J., 2019, In : Netherlands Journal of Medicine. 77, 2, p. 88

Research output: Contribution to journalArticleAcademicpeer-review